Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Olivera

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Arquivos De Gastroenterologia|March 23, 2017
EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSISJuan Lasa, Pablo Olivera
Gut|November 19, 2016
Next generation of small molecules in inflammatory bowel diseasePablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Expert Review of Clinical Immunology|February 7, 2017
JAK inhibition in inflammatory bowel diseasePablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Arquivos De Gastroenterologia|April 16, 2020
PLACEBO USE IN THE CONTEXT OF INFLAMMATORY BOWEL DISEASE CLINICAL TRIALSJuan Sebastian Lasa, Ignacio Zubiaurre, Astrid Rausch, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 18, 2018
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidencePablo Olivera, Silvio Danese, Lieven Pouillon, et al.
Journal of Gastroenterology|September 26, 2016
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic reviewLaura Martelli, Pablo Olivera, Xavier Roblin, et al.
Nature Reviews. Gastroenterology & Hepatology|January 20, 2019
Big data in IBD: a look into the futurePablo Olivera, Silvio Danese, Nicolas Jay, et al.
Current Opinion in Gastroenterology|May 3, 2017
Surgical rates in the era of biological therapy: up, down or unchanged?Pablo Olivera, Antonino Spinelli, Corinne Gower-Rousseau, et al.
Inflammatory Bowel Diseases|March 24, 2017
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center ExperiencePablo Olivera, Linda Thiriet, Amandine Luc, et al.
JPMA. the Journal of the Pakistan Medical Association|April 5, 2021
Design and health: An interdisciplinary baseline experience of product design for health needs of the Chilean elderlyJuan Carlos Briede Westermeyer, Cristhian Perez Villalobos, Pablo Olivera Morales, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Arquivos De Gastroenterologia|March 23, 2017
EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSISJuan Lasa, Pablo Olivera
Gut|November 19, 2016
Next generation of small molecules in inflammatory bowel diseasePablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Expert Review of Clinical Immunology|February 7, 2017
JAK inhibition in inflammatory bowel diseasePablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Arquivos De Gastroenterologia|April 16, 2020
PLACEBO USE IN THE CONTEXT OF INFLAMMATORY BOWEL DISEASE CLINICAL TRIALSJuan Sebastian Lasa, Ignacio Zubiaurre, Astrid Rausch, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 18, 2018
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidencePablo Olivera, Silvio Danese, Lieven Pouillon, et al.
Journal of Gastroenterology|September 26, 2016
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic reviewLaura Martelli, Pablo Olivera, Xavier Roblin, et al.
Nature Reviews. Gastroenterology & Hepatology|January 20, 2019
Big data in IBD: a look into the futurePablo Olivera, Silvio Danese, Nicolas Jay, et al.
Current Opinion in Gastroenterology|May 3, 2017
Surgical rates in the era of biological therapy: up, down or unchanged?Pablo Olivera, Antonino Spinelli, Corinne Gower-Rousseau, et al.
Inflammatory Bowel Diseases|March 24, 2017
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center ExperiencePablo Olivera, Linda Thiriet, Amandine Luc, et al.
JPMA. the Journal of the Pakistan Medical Association|April 5, 2021
Design and health: An interdisciplinary baseline experience of product design for health needs of the Chilean elderlyJuan Carlos Briede Westermeyer, Cristhian Perez Villalobos, Pablo Olivera Morales, et al.
Pageof 3